PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 15, 2021European Journal of Cancer194 citationsOpen Access

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

EGEleonora GhisoniAWAlexandre WickyHBHasna Bouchaab

Key Points

  • This research aims to assess the underreported late-onset and long-lasting immune-related adverse events during immune checkpoint inhibitor therapy.
  • Time-dependent survival analysis was utilized to evaluate the impact of late-onset irAEs on overall survival.
  • Real-world evidence collection was advocated for comprehensive characterization of these events.
  • Appropriate strategies for patient surveillance and follow-up were suggested.
  • Late-onset immune-related adverse events were found to significantly impact overall survival.
  • The analysis revealed a need for improved monitoring strategies to manage these events effectively.

Abstract

Late-onset and long-lasting irAEs are underreported but common events during ICIs therapy. Time-dependent survival analysis is advocated to assess their impact on OS. Real-world evidence is warranted to fully capture and characterise late-onset and long-lasting irAEs in order to implement appropriate strategies for patient surveillance and follow-up.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ghisoni et al. (2021) studied this question.

synapsesocial.com/papers/69deaadf4838c5c0bab0c8f8https://doi.org/10.1016/j.ejca.2021.03.010
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors2019 · 1,170 citations
  2. 2Emerging Issues and Opportunities in Health Information Technology2016 · 10 citations
  3. 3Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy2016 · 1,320 citations
  4. 4Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center2015 · 1,081 citations
  5. 5NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care2016 · 102 citations